Sugi Predict

Sugi Predict / Compounds / SCHEMBL14768636

SCHEMBL14768636

SCHEMBL14768636

Cc1cc(Cl)cc(Sc2ccc([N+](=O)[O-])cc2CN2CCSCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.42
▸ ACHE P22303 2/20 0.41
▸ L3MBTL1 Q9Y468 3/20 0.39
▸ MAPT P10636 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ CTSB P07858 1/20 0.39
▸ FAAH O00519 1/20 0.39
▸ MGLL Q99685 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14768587 0.93 LMNA (0.59) LMNASMN1; SMN2KDM4EALDH1A1ACHE
SCHEMBL14768656 0.87 LMNA (0.43) LMNASMN1; SMN2KDM4EALDH1A1ACHE
SCHEMBL15334543 0.82 LMNA (0.41) LMNASMN1; SMN2KDM4EALDH1A1L3MBTL1
SCHEMBL19720320 0.81 ALDH1A1 (0.47) LMNASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL14768596 0.80 L3MBTL1 (0.38) LMNASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL14768660 0.75 LMNA (1.00) LMNASMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL15334537 0.74 FAAH (0.44) LMNASMN1; SMN2KDM4EALDH1A1L3MBTL1
SCHEMBL13157463 0.73 ALDH1A1 (0.51) LMNASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL13108359 0.73 L3MBTL1 (0.51) LMNASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL14768634 0.71 ADORA2A (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160031841-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. 2016-02-04 — — US disclosed
US-9187425-B2 2,5-disubstituted arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2015-11-17 — — US disclosed
US-20140066446-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2014-03-06 — — US disclosed
US-8563544-B2 2,5-disubstituted arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2013-10-22 — — US disclosed
US-20130065889-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2013-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031841-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 LMNA 4120/4885SMN1; SMN2 603/4885KDM4E 2880/4885
US-20140066446-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 LMNA 4120/4885SMN1; SMN2 603/4885KDM4E 2880/4885
US-20130065889-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 LMNA 4120/4885SMN1; SMN2 603/4885KDM4E 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.